Suono Bio gets Fujifilm investment for its second-generation drug delivery tech, names new CEO

Drugs and money
Fujifilm is investing in Suono Bio’s second-generation drug delivery technology. (Getty/LIgorko)

Japan’s Fujifilm is investing (PDF) in Suono Bio’s second-generation drug delivery technology that uses speedy, formulation-independent application of therapeutics that include biologics and gene therapies.

Terms and the amount of the investment by the Tokyo-based company weren’t disclosed.

Suono Bio uses tech developed in the MIT laboratory of Robert Langer. The technology has shown preclinical activity in a scope of diseases using a diverse set of therapeutics, the company said.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

“Fujifilm has deep technical expertise and offers the chance to accelerate our development by working closely with their scientists and engineers in the future,” Langer said in a statement.

In a separate announcement, Suono Bio announced that it named Lisa Ricciardi as chief executive. Prior to joining the company, Ricciardi has worked for a variety of organizations, including Pfizer, Medco, Foundation Medicine and Essex Woodlands.

“The addition of Lisa to the team marks an important milestone for Suono Bio, particularly as we prepare for our entry to the clinic,” Dr. Carl Schoellhammer, the company’s founding chief executive, said in a statement.

Schoellhammer will take on the role of COO and serve on the board.

Suggested Articles

Clinical trial enrollment has dropped massively across the world as endocrine, cardiovascular tests being the hardest hit.

As COVID-19 continues to wreak havoc across nearly all clinical trials in the U.S., Asia and Europe, so-called virtual trials are coming to the fore.

IQVIA has kick-started a new matchmaking trial service to “accelerate treatment and vaccine development” against COVID-19.